Vanderbilt University Medical Center
21st Avenue South and Medical Center Drive
Nashville
Tennessee
37232
United States
Tel: 615-322-5000
57 articles with Vanderbilt University Medical Center
-
Results of the Phase III trial showed that Evusheld protected against progression to severe COVID-19 or death in the early outpatient treatment of mild-to-moderate COVID-19.
-
The latest EUA adjustment was based on findings that Evusheld might not be as active against certain subvariants of Omicron, but it could be if the dosage is increased.
-
Biofourmis Selected by Vanderbilt University Medical Center for CAR T-Cell Therapy Study Utilizing Tech-Enabled Remote Patient Monitoring
2/16/2022
Biofourmis announced today that Vanderbilt University Medical Center has selected Biofourmis to support a clinical study measuring the safety and efficacy of monitoring patients in a home-like outpatient setting after receiving a leading oncology drug.
-
The FDA has approved emergency use authorization for AstraZeneca's Evusheld cocktail as prophylaxis against COVID-19 infection in adults and adolescents aged at least 12 years.
-
The Pfizer-BioNTech booster shot is now authorized for people over 18 and 65 who are immunocompromised, at high risk due to their work or living situation and front-line healthcare workers.
-
Touchlight and Vanderbilt University Medical Center collaborate on DARPA Pandemic Prevention Platform programme to develop synthetic DNA-based antibody to protect against emerging threats
7/28/2021
Touchlight, the leading synthetic DNA manufacturer, is collaborating with the Vanderbilt Vaccine Center at Vanderbilt University Medical Center as part of the DARPA P3 programme.
-
The Leukemia & Lymphoma Society Launches IMPACT Research Grants to Help Underserved Patients Access Clinical Trials
5/6/2021
Collaborations with Mayo Clinic, Vanderbilt University Medical Center and Weill Cornell Medicine will Increase Representation of Geographically, Ethnically and Economically Underserved Communities in Clinical Trials
-
Vanderbilt Seeks Volunteers for COVID-19 Clinical Trial
4/12/2021
Vanderbilt University Medical Center is actively enrolling volunteers in an ongoing clinical treatment study for adults with COVID-19.
-
Vanderbilt University Medical Center and IDBiologics Ally in Race to Develop Breakthrough Medicines for COVID-19
5/7/2020
Vanderbilt University Medical Center and the biotech company IDBiologics, Inc., have joined forces to develop novel monoclonal antibody medicines that could potentially treat COVID-19 or prevent infection from the causative virus called SARS-CoV-2.
-
Twist Bioscience Partners with Vanderbilt University Medical Center to Supply Critical Products and Identify Antibody Therapeutics for COVID-19
3/26/2020
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Vanderbilt University Medical Center (VUMC) to supply synthetic genes and antibodies for the development of therapies for COVID-19. In addition, Twist Biopharma, a division of Twist Bioscience, will provide cus
-
Ology Bioservices, Vanderbilt University Medical Center to Develop, Manufacture Monoconal Antibody for Treatment, Prevention of Infection With COVID-19 Virus for Department of Defense
3/23/2020
The Department of Defense awarded a contract valued at $14 million with Ology Bioservices Inc., a biologics contract development and manufacturing organization, to develop and manufacture a monoclonal antibody for treatment and prevention of infection with the COVID-19 virus.
-
Batavia Biosciences to deploy Horizon Discovery’s CHO cell technology to develop anti-Zika biotherapeutic with Vanderbilt University Medical Center and IDBiologics
9/3/2019
Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines.
-
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi and six major health systems.
-
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
-
IBM Watson Health Invests in Research Collaborations with Leading Medical Centers to Advance the Application of AI to Health
2/13/2019
Initial projects focus on practical application of AI to improve care, enhance health team workflow, and better understand human-machine interactions
-
GE Healthcare, Vanderbilt University Medical Center Partner for Safer, More Precise Immunotherapy Cancer Treatment
1/6/2019
Artificial Intelligence (AI)-powered applications will help predict how individual patients will respond to immunotherapies in advance of treatment
-
Citing safety concerns, a watchdog organization is calling on the National institutes of Health to halt enrollment in a clinical trial evaluating a treatment for sepsis that the organization said is risky and flawed.
-
Goldfinch Bio Announces Collaborations with Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to Augment World's Largest Genomic Registry of Patients with Kidney Disease
10/17/2017
Goldfinch Bio today announced collaborations with the Icahn School of Medicine at Mount Sinai and Vanderbilt University Medical Center to generate genomic data on over 1,500 patients with proteinuric kidney disease.
-
Bayer And Vanderbilt University Medical Center Collaborate To Develop New Therapies Against Kidney Diseases
9/11/2017
-
Cancer Prevention Pharma In Collaboration With The NCI And Vanderbilt University Medical Center Initiates Phase II Trial To Evaluate CPP-1X In Patients With High Risk Of Gastric Cancer
7/17/2017